Featured Research

from universities, journals, and other organizations

An Aspirin A Day May Keep Colon Cancer Away, Dartmouth Researchers Find

Date:
March 6, 2003
Source:
Dartmouth Medical School
Summary:
A seven-year study led by Dartmouth Medical School researchers shows that a daily dose of aspirin can be effective in reducing the risk of colon adenomas – benign tumors that can develop into cancer if left in the bowel.

LEBANON, NH -- A seven-year study led by Dartmouth Medical School researchers shows that a daily dose of aspirin can be effective in reducing the risk of colon adenomas – benign tumors that can develop into cancer if left in the bowel.

The study, conducted jointly by doctors and researchers from Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center in Lebanon, NH, and at several other institutions across North America, confirms indications from non-randomized studies that low-dose aspirin may protect against cancers of the colon and rectum. The final results of the study were published in the March 6, 2003 issue of the New England Journal of Medicine.

Dr. John Baron was lead author of the article, and co-author of another report in the NEJM that also found that aspirin protected against adenomas of the colon and rectum. He noted that the findings of the two studies show that low doses of aspirin do protect against the pre-cancerous polyps, and so there is good reason to believe aspirin probably reduces rates of colorectal cancer itself. This will be particularly valuable for people who are at increased risk for cancer because they have had colon adenomas (polyps) or because they have previously been treated for colorectal cancer.

The randomized, double-blind study, conducted between 1994 and 2001, looked at over 1100 patients with previously diagnosed colorectal adenomas. Some patients received aspirin – either 81 mg or 325 mg – while others received a placebo. Interestingly, the group receiving the smaller dose of aspirin – 81-mg, or the equivalent of one baby aspirin – showed a lower incidence of recurring polyps than did those treated with the larger dose of aspirin – 325 mg or the equivalent of a standard adult aspirin.

Overall, those treated with a daily dose of baby aspirin found their risk of polyps reduced 19 percent and their risk of advanced lesions reduced by more than 40 percent.

The companion study, conducted among patients with a history of cancer of the colon or rectum, tested a regular aspirin tablet (325 mg) against placebo. It showed even larger reductions in the occurrence of adenoma – about a 35% reduction.

Although aspirin is generally a safe drug, Baron noted that it can have adverse effects for some individuals. Before people embark on a daily aspirin regimen, they should check with their doctor, he said. And, he stressed that just taking aspirin is not enough to assure freedom from colon cancer.

"Aspirin is not a magic bullet. Although the incidence was reduced, all the polyps didn't go away in our study. Regular screenings, perhaps including colonoscopies, are still important."


Story Source:

The above story is based on materials provided by Dartmouth Medical School. Note: Materials may be edited for content and length.


Cite This Page:

Dartmouth Medical School. "An Aspirin A Day May Keep Colon Cancer Away, Dartmouth Researchers Find." ScienceDaily. ScienceDaily, 6 March 2003. <www.sciencedaily.com/releases/2003/03/030306080102.htm>.
Dartmouth Medical School. (2003, March 6). An Aspirin A Day May Keep Colon Cancer Away, Dartmouth Researchers Find. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2003/03/030306080102.htm
Dartmouth Medical School. "An Aspirin A Day May Keep Colon Cancer Away, Dartmouth Researchers Find." ScienceDaily. www.sciencedaily.com/releases/2003/03/030306080102.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins